These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10770750)

  • 1. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
    Braz VA; Holladay LA; Barkley MD
    Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
    Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.
    King RW; Klabe RM; Reid CD; Erickson-Viitanen SK
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1640-6. PubMed ID: 12019069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer.
    Jaju M; Beard WA; Wilson SH
    J Biol Chem; 1995 Apr; 270(17):9740-7. PubMed ID: 7537269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3'-fluorothymidine analogue 5'-triphosphates.
    Wińska P; Miazga A; Poznański J; Kulikowski T
    Antiviral Res; 2010 Nov; 88(2):176-81. PubMed ID: 20739003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
    Cruchaga C; Odriozola L; Andréola M; Tarrago-Litvak L; Martínez-Irujo JJ
    Biochemistry; 2005 Mar; 44(9):3535-46. PubMed ID: 15736963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
    Patel M; Ko SS; McHugh RJ; Markwalder JA; Srivastava AS; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Seitz SP
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2805-10. PubMed ID: 10522695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.